ライフサイエンスコーパス: antifungal agent

1 bilities of Candida spp. to this widely used antifungal agent.

2 ntibiotics, is a Streptomyces-derived potent antifungal agent.

3 s agent remains a viable systemically active antifungal agent.

4 riconazole should be considered a first-line antifungal agent.

5 munomodulatory activity and toxicity of this antifungal agent.

6 e (BCYE alpha medium) and with natamycin, an antifungal agent.

7 sceptibility to azoles, the most widely used antifungal agent.

8 is antibacterial aminoglycoside into a novel antifungal agent.

9 , showing the effectiveness of the REO as an antifungal agent.

10 nal release of a cationic beta-peptide-based antifungal agent.

11 C2'deOAmB is an exceptionally promising new antifungal agent.

12 eatment with ketoconazole, a clinically used antifungal agent.

13 med biofilms, which are resistant to current antifungal agents.

14 diagnostic tools and the pharmacokinetics of antifungal agents.

15 ibilities of Candida spp. to these important antifungal agents.

16 ing pheromones, tunicamycin, and azole-class antifungal agents.

17 from seeded blood cultures in the absence of antifungal agents.

18 suspensions of Candida spp., with or without antifungal agents.

19 th and without the addition of commonly used antifungal agents.

20 for a spectrum of both novel and established antifungal agents.

21 me species vary in their susceptibilities to antifungal agents.

22 , and the safety and efficacy of appropriate antifungal agents.

23 pulations, including increased resistance to antifungal agents.

24 ast species with decreased susceptibility to antifungal agents.

25 potent activity of selected, newer triazole antifungal agents.

26 tibacterial agents, it is also an issue with antifungal agents.

27 ells are relatively resistant to many common antifungal agents.

28 ida with reduced susceptibility to the azole antifungal agents.

29 orted to exhibit decreased susceptibility to antifungal agents.

30 ificance of in vitro resistance to the newer antifungal agents.

31 a new enzymatic target for antibacterial or antifungal agents.

32 95 to 99% agreement) for all the species and antifungal agents.

33 cterial agents, and it is also an issue with antifungal agents.

34 acrolide antibiotics are naturally occurring antifungal agents.

35 chinocandins were higher than those of other antifungal agents.

36 serve as a lead structure for a new class of antifungal agents.

37 icans, inhibitors of Ess1 might be useful as antifungal agents.

38 and remains highly susceptible to available antifungal agents.

39 minimum fungicidal concentrations (MFCs) of antifungal agents.

40 of kanamycin A, show very strong activity as antifungal agents.

41 OPC, possibly reducing the usage of systemic antifungal agents.

42 deal candidates for the development of novel antifungal agents.

43 neoformans and represents a novel target for antifungal agents.

44 iated with long-term treatment with existing antifungal agents.

45 ghly susceptible to both new and established antifungal agents.

46 pressive rapamycin analogs have potential as antifungal agents.

47 ticular significance due to the need for new antifungal agents.

48 eptibilities of Candida spp. to a variety of antifungal agents.

49 as created a need for the development of new antifungal agents.

50 s of several synthetic and naturally derived antifungal agents.

51 ains inhibited in ergosterol biosynthesis by antifungal agents.

52 turase (5-desaturase), may lead to effective antifungal agents.

53 is a potential target for antibacterial and antifungal agents.

54 FDA-approved member of the triazole class of antifungal agents.

55 n that should inspire the development of new antifungal agents.

56 the potential to decrease the use of empiric antifungal agents.

57 should focus on long-term administration of antifungal agents.

58 rusei were classified as susceptible to both antifungal agents.

59 ocular tissues despite prolonged exposure to antifungal agents.

60 e by systemic administration of conventional antifungal agents.

61 lems associated with the use of conventional antifungal agents.

62 ective advantage in the presence of specific antifungal agents.

63 i were classified as susceptible (S) to both antifungal agents.

64 nd resistance rates of newer and established antifungal agents.

65 esulted in an increased demand for new azole antifungal agents.

66 inical features may guide the use of initial antifungal agents.

67 al communities displaying resistance to most antifungal agents.

68 munity, underscoring the urgent need for new antifungal agents.

69 of birth defects previously linked to azole antifungal agents.

70 opathies, and broad spectrum antibiotics and antifungal agents.

71 e that belongs to the syringomycin family of antifungal agents.

72 the pharmacology and pediatric use of newer antifungal agents.

73 ced susceptibility to these well-established antifungal agents.

74 vs 18%, p=0.03) and concomitant therapy with antifungal agents (75% vs 9%, p=0.006).

75 f a key intermediate in the synthesis of the antifungal agent alternaric acid is also described.

76 Amphotericin is the most commonly used antifungal agent, although fluconazole is being used mor

77 The membrane-active antifungal agent amphotericin B (AmB) is one of the few

78 argeting antibiotic gramicidin and the known antifungal agent amphotericin B and were not toxic at th

79 The susceptibility of the isolates to the antifungal agents amphotericin B, flucytosine, fluconazo

80 . tropicalis, and 7 C. krusei) against seven antifungal agents (amphotericin B, fluconazole, voricona

81 riconazole as well as four licensed systemic antifungal agents (amphotericin B, flucytosine, fluconaz

82 and 48-h BMD MICs was observed for all three antifungal agents: amphotericin B, 99.1% and 97%, respec

83 acology and clinical indications of existing antifungal agents and also the development of new broad-

84 e others had a good response to a variety of antifungal agents and antiretroviral therapy.

85 ff values (ECVs) for the systemically active antifungal agents and both common and uncommon species o

86 e new 2,3-dideoxyglucosides can be useful as antifungal agents and condiments in foods.

87 the mechanisms of action of these classes of antifungal agents and demonstrate the potential utility

88 Advances in antifungal agents and diagnostic methods offer the poten

89 New antifungal agents and diagnostic tests may improve the o

90 alivary histatins (Hsts) are potent in vitro antifungal agents and have great promise as therapeutic

91 findings raise questions about the effect of antifungal agents and health care exposures (e.g., yogur

92 The limitations of the current antifungal agents and opportunities for new developments

93 for the development of urgently needed novel antifungal agents and strategies.

94 ude validation of 24-h reading times for all antifungal agents and the establishment of species-speci

95 ndard for investigating both the activity of antifungal agents and the pathogenesis of this disease.

96 this clinically vital but also highly toxic antifungal agent, and (iii) suggest that the capacity fo

97 sible small molecules: pyrrolnitrin, a known antifungal agent, and a chromene that potently enhances

98 otericin B was selected as a membrane-active antifungal agent, and caspofungin was selected as a cell

99 e isolated before the widespread use of this antifungal agent, and only three were in fact drug resis

100 tic route a promising target for herbicides, antifungal agents, and antibiotics.

101 sive strategies, dosing, durations of use of antifungal agents, and definitions of invasive infection

102 stic methods, the pharmacology and dosing of antifungal agents, and the absence of interventional pha

103 l agents (quinolones, antiviral therapy, and antifungal agents), antiemetic agents, and analgesic age

104 an important public health concern, and new antifungal agents are highly desirable.

105 Efficient and pathogen-specific antifungal agents are required to mitigate drug resistan

106 h superior in some cases compared with older antifungal agents, are still far from satisfactory.

107 for rational design of new, more efficacious antifungal agents as well as insight into the molecular

108 mportant implications for the development of antifungal agents, as well as the understanding of polym

109 Clinical Question: Are antifungal agents associated with lower rates of mortali

110 Caspofungin is a safe antifungal agent at vitreal concentrations of 0.41 to 4.

111 sk factors (including candidiasis and use of antifungal agents at the current examination, a low CD4:

112 In bottles containing antifungal agents, Bactec FX recovered 83.1% of isolates

113 In the absence of antifungal agents, Bactec FX recovered 97.4% of Candida

114 Our data suggest that the natural antifungal agent beta-glucanase may support morphologic

115 Drugs targeting calcineurin are potent antifungal agents but also perturb human immunity thereb

116 ed the susceptibility of planktonic cells to antifungal agents, but an antagonistic effect was observ

117 the susceptibilities of filamentous fungi to antifungal agents by the Clinical and Laboratory Standar

118 s were tested 20 times each against the five antifungal agents by using a common lot of RPMI agar.

119 Antifungal agents can effectively treat mucosal candidia

120 Antifungal agents can effectively treat mucosal candidia

121 -step synthesis of the highly functionalized antifungal agent CANCIDAS (caspofungin acetate, 2) is de

122 id antifungal susceptibility testing for the antifungal agent caspofungin can be performed using flow

123 d in the treatment of alcohol abuse) and the antifungal agent chlordantoin.

124 also identified the approved small-molecule antifungal agent ciclopirox as a novel pan-histone demet

125 visiae conferred increased resistance to the antifungal agent cilofungin (LY121019), an echinocandin

126 The combination of antifungal agents (cinnamon bark oil, zinc gluconate and

127 log2 dilution range for the respective yeast-antifungal agent combinations.

128 that are typically resistant to traditional antifungal agents, could potentially have a role in devi

129 of birth defects previously linked to azole antifungal agents: craniosynostosis, other craniofacial

130 The biofilms are resistant to a range of antifungal agents currently in clinical use, including a

131 m temperature incubation and the addition of antifungal agents decreased growth of Candida species in

132 bitors used in the study were nitroimidazole antifungal agents, diltiazem, verapamil, and troleandomy

133 n bonding and decrease the susceptibility of antifungal agents during chemotherapy.

134 ecipients vary, particularly with regards to antifungal agent employed, and duration of therapy.

135 e promising leads for the development of new antifungal agents, especially against C. neoformans.

136 in the clinical laboratory for the four new antifungal agents evaluated.

137 This is a rational approach because existing antifungal agents fail to eradicate the infection in the

138 CYP51), complexed with posaconazole, another antifungal agent fluconazole and an experimental inhibit

139 s of Candida glabrata resistant to the azole antifungal agent fluconazole was evaluated on a collecti

140 Inhibitors of CYP51 include triazole antifungal agents fluconazole and itraconazole, drugs us

141 f these agents with those of the established antifungal agents fluconazole, itraconazole, amphoterici

142 dubliniensis are susceptible to established antifungal agents, fluconazole-resistant strains have be

143 kn7, governs sensitivity to Na+ ions and the antifungal agent fludioxonil, negatively controls melani

144 The MICs of various antifungal agents for germinated conidia were almost ide

145 For the prototype panel, we chose eight antifungal agents for in vitro testing (amphotericin B,

146 earlier diagnosis and selection of effective antifungal agents for patients with IA.

147 The role of newer antifungal agents for this population, such as the new a

148 Flucytosine and itraconazole are the only antifungal agents for which the Clinical Laboratory and

149 A limited number of antifungal agents from only a few drug classes are avail

150 A new class of antifungal agents has been discovered which exert their

151 Overuse of antifungal agents has resulted in the selection of natur

152 Clinical needs for novel antifungal agents have altered steadily with the rise an

153 Calcineurin inhibitors (CNI) and azole antifungal agents have been reported to interact in a di

154 Meanwhile, six new antifungal agents have just reached, or are approaching,

155 in reports of fungal resistance to multiple antifungal agents have made fungal infections a major th

156 The newer systemic antifungal agents have no significant advantage over gri

157 agnostic systems and the introduction of new antifungal agents have significantly improved outcomes i

158 s is intimately dependent on the efficacy of antifungal agents; however, fungi that are resistant to

159 ndins, but no change in sensitivity to other antifungal agents; (ii) in vitro glucan synthase activit

160 ility that MtDef5 might be useful as a novel antifungal agent in transgenic crops.

161 e, a detailed understanding of the available antifungal agents in children is crucial for the success

162 s and mechanisms of action of all classes of antifungal agents in clinical use or with clinical poten

163 concentrations of semisynthetic pneumocandin antifungal agents in human plasma.

164 of chitin synthase, effective as therapeutic antifungal agents in humans and easily degradable insect

165 cleoside antibiotics that act as therapeutic antifungal agents in humans and easily degraded insectic

166 ingly reminiscent of the reduced efficacy of antifungal agents in immunocompromised animals.

167 se of prophylactic systemic antibacterial or antifungal agents in patients with necrotizing pancreati

168 permitting earlier selection of appropriate antifungal agents in the clinical setting.

169 The combination of antifungal agents in the emulsions has demonstrated to b

170 ach isolate was tested 20 times with the two antifungal agents in the five laboratories by using a lo

171 aphic analysis of the oxidase and the use of antifungal agents in the prophylaxis of chronic granulom

172 nefit to adding oral voriconazole to topical antifungal agents in the treatment of severe filamentous

173 This review summarizes information on new antifungal agents, including current data on their clini

174 features, and also reviews the use of newer antifungal agents, including lipid-associated amphoteric

175 Newer antifungal agents, including voriconazole and caspofungi

176 test whether posaconazole, a broad-spectrum antifungal agent inhibiting ergosterol biosynthesis, exh

177 Bifonazole, a broad spectrum antifungal agent, inhibits monooxygenase activity and in

178 The echinocandin class of antifungal agents is considered to be the first-line tre

179 A red flag has been raised with the triazole antifungal agents, itraconazole and voriconazole, causin

180 (ISAV) is a novel, broad-spectrum, triazole antifungal agent (IV and by mouth [PO]) developed for th

181 unomodulatory properties, the newer class of antifungal agents, known as echinocandins, has the poten

182 e stereochemical determination of the potent antifungal agents leupyrrin A1 and B1 and the total synt

183 Its resistance to certain antifungal agents makes it difficult to treat, especiall

184 tencies of the new triazole and echinocandin antifungal agents may provide effective therapeutic opti

185 st that itraconazole, an orally administered antifungal agent, may be an effective adjunctive therapy

186 susceptibilities of Candida spp. to the new antifungal agent MK-0991, a glucan synthase inhibitor.

187 representative of the echinocandin class of antifungal agents, MK-0991.

188 Strategies for the appropriate use of antifungal agents need to be developed to prevent furthe

189 ns strains are particularly resistant to the antifungal agents now in use.

190 The pneumocandins are potent antifungal agents of the echinocandin class which are un

191 elective synthesis of the acyclic portion of antifungal agent plakinic acid A, containing two remotel

192 rise of fungi that are resistant to existing antifungal agents poses a substantial threat to human he

193 lity testing of filamentous fungi (molds) to antifungal agents, quality control (QC) disk diffusion z

194 The overall agreement for each antifungal agent ranged from 96% for ravuconazole to 100

195 Voriconazole was 1 of 2 antifungal agents recommended for treatment of fungal in

196 ylaxis, consensus on the strategy, choice of antifungal agent(s), route of administration, and durati

197 spp., enable clinicians to more quickly make antifungal agent selections, and potentially decrease pa

198 as defined as the concentration at which the antifungal agent significantly inhibits the organism.

199 These compounds include anticancer and antifungal agents, statins, alverine citrate, and dyclon

200 it 3-4 times more potent than commonly used antifungal agents such as ketoconazole (1.5 muM) or itra

201 ocandins but are not yet available for older antifungal agents, such as amphotericin B, flucytosine,

202 Novel antifungal agents, such as the echinocandins and the sec

203 Prophylactic use of antifungal agents, such as the echinocandins, during per

204 dk7 and raises the possibility of developing antifungal agents targeting CAKs.

205 ineurin and provides a foundation to develop antifungal agents targeting calcineurin to deploy agains

206 nvestigated the MIC reproducibility of seven antifungal agents tested against 25 dermatophyte isolate

207 k and reference panels were observed for all antifungal agents tested against the 99 clinical isolate

208 The antifungal agents tested included amphotericin B, flucyt

209 Antifungal agents tested included ciclopirox, fluconazol

210 Of the antifungal agents tested, ravuconazole and voriconazole

211 Sertaconazole nitrate is an antifungal agent that exhibits anti-inflammatory activit

212 Voriconazole is a new triazole antifungal agent that has potent activity against many i

213 Micafungin is an echinocandin antifungal agent that has recently been approved for the

214 Caspofungin is a synthetic echinocandin antifungal agent that inhibits the synthesis of beta(1,3

215 Nystatin (nys) is an antifungal agent that preferentially forms ion channels

216 gs demonstrate that EntV has potential as an antifungal agent that targets virulence rather than viab

217 We determined whether cercosporamide, an antifungal agent that was recently shown to act as a uni

218 Despite the availability of powerful antifungal agents that are active against Cryptococcus n

219 a-Peptides comprise a promising new class of antifungal agents that could help address problems assoc

220 s been realized with the introduction of new antifungal agents that have proved to be safer than thos

221 Echinocandins are a group of antifungal agents that target 1,3-beta-glucan synthase,

222 While the development of new antifungal agents that target the essential enzyme, dihy

223 In the presence of antifungal agents, the Bactec FX recovery time was signi

224 sence of therapeutic levels of commonly used antifungal agents, the Bactec FX system demonstrated a s

225 o effect on the toxicity of a novel class of antifungal agents, the dicationic aromatic compounds (DA

226 Among the systemically active antifungal agents, the echinocandins appear to be the mo

227 road-spectrum triazoles and a newer class of antifungal agents, the echinocandins.

228 For BC bottles without the addition of antifungal agents, the median LTD for VersaTREK was 2.2

229 Despite treatment with antifungal agents, the mortality rate attributed to thes

230 Due to their effectiveness as antifungal agents, three semisynthetic derivatives have

231 d interest in studying novel combinations of antifungal agents to determine whether superior outcomes

232 ntrations (MECs) (CLSI M38-A method) of five antifungal agents to identify optimal testing guidelines

233 There is significant clinical need for new antifungal agents to manage infections with pathogenic s

234 ME1111 is a novel small molecule antifungal agent under development for the topical treat

235 he era of modern immunosuppressive and newer antifungal agent use have not been defined.

236 Ciclopirox olamine (CPX), an off-patent antifungal agent used to treat mycoses of skin and nails

237 ism and fluconazole remained the predominant antifungal agent used.

238 s of the four currently available classes of antifungal agents used in the management of systemic fun

239 We conclude that in vitro resistance to antifungal agents used in the treatment of cryptococcosi

240 linical efficacy and toxicity of the various antifungal agents used to prevent infection, and offers

241 d to be less hemolytic than the FDA-approved antifungal agent voriconazole (VOR).

242 cycles exemplified by the methylation of the antifungal agent voriconazole.

243 All 35 patients were treated with antifungal agents (voriconazole, with or without liposom

244 tration of glucose decreased the activity of antifungal agents; voriconazole was the most affected dr

245 17 responses remained defective even when an antifungal agent was administered throughout DSS exposur

246 ical agreement (CA) between methods for each antifungal agent was assessed using previously determine

247 A review of common topical antifungal agents was done.

248 In the course of screening for antifungal agents we have discovered a novel compound is

249 With the limited choices of topical antifungal agents, we were faced with Cladosporium kerat

250 Membrane permeability changes caused by the antifungal agent were measured by flow cytometry using p

251 The MICs for seven antifungal agents were determined in a central laborator

252 Effects of glucose on the susceptibility of antifungal agents were investigated against Candida spp.

253 Antifungal agents were not associated with obesity (OR =

254 The in vitro assays of free antifungal agents were performed against five fungal str

255 ve QC limits for the two QC strains and five antifungal agents when tested by the Etest methodology a

256 Breakpoints are used to predict whether an antifungal agent will be clinically effective against a

257 s to characterize the mechanism of action of antifungal agents will be of great use in the antifungal

258 d suggest that development of CYP51-specific antifungal agents will continue to be a challenge.

259 ich no resistance could be identified and an antifungal agent with activity against diverse fungal pa

260 Caspofungin acetate, a new antifungal agent with minimal toxicity, may provide a be

261 Anidulafungin is an echinocandin antifungal agent with potent activity against Candida sp

262 e efficacy of anidulafungin, an echinocandin antifungal agent with potent anti-Candida activity, in t

263 f any positive test can obviate the need for antifungal agents with a negative predictive value of 10

264 e AG backbone, interesting antibacterial and antifungal agents with a novel mechanism of action have

265 Biophysical interactions between antifungal agents with glucose molecules were investigat

266 There is an important medical need for new antifungal agents with novel mechanisms of action to tre

267 their metabolic activity in the presence of antifungal agents with that in their absence.

268 da spp. and C. neoformans against a range of antifungal agents with the exceptions only of miconazole

269 infections is now possible with a variety of antifungal agents, with different spectrums of activity,

270 sceptible to the currently licensed systemic antifungal agents, with the exception of voriconazole.